Exagen Inc. Appoints Paul Kim to Board of Directors
July 24 2023 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing
solutions, announced today that Paul Kim has been appointed as a
member of the Exagen Board of Directors, effective July 24, 2023.
Mr. Kim currently serves as Chief Financial Officer of Fulgent
Genetics (Nasdaq: FLGT), a full-service genomic testing company
built around a foundational technology platform. He has held that
position since February 2016 and led growth initiatives increasing
revenues from $10M in 2015 to $990M in 2021, during the COVID-19
era. Mr. Kim has over 30 years working in accounting and finance,
and over 15 years as a Chief Financial Officer of several publicly
traded companies. Mr. Kim is a Certified Public Accountant and a
graduate of the University of California at Berkeley.
“We are thrilled to welcome Paul to our Board of Directors at
Exagen. His leadership experience and background in operating
profitable, sound businesses is invaluable,” said John Aballi,
President and CEO of Exagen. “I look forward to learning from his
30 plus years of leadership in business.”
“I am delighted to join the Board of Directors at Exagen,” said
Paul Kim. “The Company has accomplished an enormous amount over the
past few years, cementing its foothold in the large and underserved
autoimmune disease market. What has impressed me most is its
IP-protected technology and proven utility of products. Those with
John’s leadership and overall strategy, which include business and
operational goals, is a recipe for success.”
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic,
prognostic, and monitoring testing solutions. Exagen is a patient
focused, discovery driven organization built on the success of
AVISE® testing and is investing in its product pipeline to support
patients throughout their autoimmune diagnosis and treatment
journeys. The goal at Exagen is to assist patients, physicians, and
payors by enabling precision medicine. Exagen is located in San
Diego County.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward-Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements
regarding: Exagen's goals and strategies; the potential
utility and effectiveness of Exagen's services and
testing solutions that are currently available or in its
development pipeline; the expected benefits of Mr. Kim’s position
with Exagen; the size of and Exagen’s competitive advantage
within the autoimmune disease market;
and Exagen's potential growth and success and its ability
to continue to grow and succeed. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: delays in reimbursement and coverage decisions from
Medicare and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products among rheumatologists, patients, third-party
payors and others in the medical community; Exagen’s ability to
successfully execute on its business strategies; third party payors
not providing coverage and adequate reimbursement for Exagen’s
testing products, including Exagen’s ability to collect on funds
due; Exagen’s ability to obtain and maintain intellectual property
protection for its testing products; regulatory developments
affecting Exagen’s business; and other risks described in Exagen’s
prior press releases and Exagen’s filings with the Securities and
Exchange Commission (“SEC”), including under the heading “Risk
Factors” in Exagen’s Annual Report on Form 10-K for the year ended
December 31, 2022 and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Exagen
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Contacts:Investors
RelationsExagen Inc.Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024